| Company: | Stem Cell Innovations, Inc. (SCI) |
| Symbol: | SCLL.OB |
| History: | In February 2006, Stem Cell Innovations, Inc. (formerly known as Interferon Sciences, Inc.) acquired Amphioxus Cell Technologies, Inc. in a merger. Amphioxus Cell Technologies was founded in 1995 with a focus on drug discovery and toxicology testing. Amphioxus's cell biology capabilities were expanded with the acquisition from Plurion, Inc. of a license to patents and patent applications important for the development and use of human pluripotent stem cells. |
| Markets: | Drug discovery and development, food supplements, nutraceuticals, cosmetics and chemical industry. |
| Employees: | SCI currently employs 20 employees divided between two R&D sites. |
| Facilities: | A state-of-the art R&D facility in Houston, Texas. In addition, SCI has a European R&D site based in Leiden, The Netherlands and an office located in Scotch Plains, New Jersey. |
